Shanghai Haohai Biological Reports Full-Year Income Retreat Amid VBP Pressures
Shanghai Haohai Biological Technology Co., Ltd. has reported a retreat in its full-year net income, reflecting the intensifying impact of China's centralized procurement policies. The decline underscores the challenges facing domestic medtech leaders as they navigate margin compression in ophthalmology and heightened competition in the medical aesthetics market.